The Impact of Cladribine Tablets on Cognition Over One Year in Patients With Multiple Sclerosis
In a preliminary observational study of 14 middle-aged MS patients, those newly started on cladribine tablets showed no decline in cognitive performance over one year. Cognitive tests indicated that total correct scores on the PASAT and delayed recall on the SRT trended toward improvement.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Limited
- Outcome
- Negative
Why it matters
These findings suggest that cladribine may have a stabilizing effect on cognition in MS patients, which is important for understanding the long-term impact of this treatment on brain health.
What this does not prove
The study is preliminary and has a small sample size, limiting the robustness of the findings and their generalizability.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- Not reported
- Randomised
- No
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Middle aged, 50.2 ± 10.8 years, 57.1% relapsing-remitting MS and 42.9% secondary progressive MS
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceThe Impact of Cladribine Tablets on Cognition Over One Year in Patients With Multiple Sclerosis: A Preliminary Study. ↗DOI: 10.1002/brb3.71844
Supporting passages (9)
study phaseCONCLUSION: In this preliminary study, no clear decline in cognitive performance was detectable over one year in patients newly started on cladribine tablets.
study designThis study aimed to investigate the one-year impact of cladribine tablets on cognition in multiple sclerosis.
randomizedOur previous study showed cortical gray matter lesion stability over one year after the start of cladribine, though its effect on cognition is not well known.
populationMETHODS: Fourteen MS subjects [age (mean ± SD) 50.2 ± 10.8, 7.14% men, 57.1% relapsing-remitting MS (n = 8), 42.9% secondary progressive (n = 6), expanded disability status scale 4.1 ± 2.1] were administered the Brief Repeatable Battery of Neuropsychological Tests (BRB-N) and the Stroop Color and Word Test (Stroop) at an average of 1.5 months from cladribine start.
findingsAfter one year, no worsening was noted on any cognitive test.
outcomeCONCLUSION: In this preliminary study, no clear decline in cognitive performance was detectable over one year in patients newly started on cladribine tablets.
limitationsTitle: The Impact of Cladribine Tablets on Cognition Over One Year in Patients With Multiple Sclerosis: A Preliminary Study.
peer reviewedPublication types: Journal Article
subjectsMeSH terms: Humans; Cladribine; Male; Female; Middle Aged; Adult; Immunosuppressive Agents; Cognition; Multiple Sclerosis; Neuropsychological Tests; Multiple Sclerosis, Relapsing-Remitting; Tablets; Cognitive Dysfunction
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.